Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) today announced encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens. The company completed Group 1 surgeries in August and September 2025, and all patients have now completed their one-month postoperative exams, showing Corrected Distance Visual Acuity (CDVA) ranging from 20/32 to 20/25.
'We are thrilled by the visual outcomes we’re seeing in our first group of patients,' said Dean Burns, President and CEO of Ocumetics. 'These results have met, and in some cases, exceeded internal expectations at this early stage of recovery. Every Group 1 patient is showing steady improvement with visual acuity.' Patients in Group 1 began the study with significantly impaired distance vision due to cataracts, making the visual gains seen as early as one month particularly encouraging.
Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, added, 'Achieving 20/32 or better vision this soon after surgery is remarkable. These data highlight the excellent optical quality and stability of the Ocumetics Lens and give us great confidence as we advance to the next patient groups.' The primary objectives of Group 1 were to confirm safety, evaluate surgical technique, and assess distance vision restoration. The results to date demonstrate that the Ocumetics Lens performs as designed, providing safe implantation and strong optical performance.
'We’re seeing early proof of what we set out to achieve; a next generation intraocular lens that gives a patient the vision they once had,' added Burns. 'Our focus now is on maintaining our momentum as we advance to Group 2 and 3 surgeries.' Planning for Group 2 surgeries is now underway, with updates to follow in the coming weeks.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is in the first-in-human early feasibility study phase of a technology designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The lens is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses.
For further information, contact Dave Burwell, Director, Investor Relations, at dave.burwell@ocumetics.com or (403) 410-7907. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. This news release includes forward-looking statements under applicable Canadian securities legislation, which involve risks and uncertainties that may cause actual results to differ materially. The company disclaims any intention to update or revise forward-looking statements except as required by law. View the original release on newmediawire.com.
